Previous 10 | Next 10 |
AMZEEQ is the First FDA Approved Topical Form of Minocycline and the Company’s First Commercial Launch AMZEEQ Offers Efficacy with Low Systemic Absorption List price of $485 Competitive Against Current Acne Market Leaders REHOVOT, Israel and BRIDGEWATER, N...
NEW YORK , Dec. 11, 2019 /PRNewswire/ -- Carolina Financial Corporation (CARO) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of CARO to United Bankshares, Inc. for 1.13 United shares per CARO share. If you are ...
Foamix ( FOMX ) is an Israeli biotech company that has a number of dermatological products in various stages of clinical trials and one already FDA-approved and about to launch (January 2020). It is merging with Menlo ( MNLO ), which has another interesting product currently in Phase II clin...
REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, announced today that David Domzalski, Chief Executive Officer, will provide a corp...
REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (Foamix or the Company), a specialty pharmaceutical company, today announced the completion of Phase 2 clinical trial enrollment of FCD105 for the treatment of moderate-to-sev...
Merger activity increased with seven new deals announced and two deals closing. Deal Statistics New Deals The acquisition of Carbonite (CARB) by Open Text Corporation (OTEX) for $1.42 billion or $23.00 per share in cash. We added CARB as a potential deal to the Deals in the Work...
NEW YORK , Nov. 15, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City , is investigating Foamix Pharmaceuticals, Ltd. ("Foamix" or the "Compa...
Foamix Pharmaceuticals Ltd. (FOMX) Q3 2019 Earnings Conference Call November 12, 2019 8:00 AM ET Company Participants Michael Wood - LifeSci Advisors Dave Domzalski - Chief Executive Officer Matt Wiley - Chief Commercial Officer Steve Basta - Chief Executive Officer, Menlo Ther...
The following slide deck was published by Foamix Pharmaceuticals Ltd. in conjunction with their 2019 Q3 earnings Read more ...
Shares of Foamix Pharmaceuticals (NASDAQ: FOMX) stock crashed in early trading Monday after the Israeli dermatological treatment company announced an agreement to acquire the competing, revenue-less pharmaceutical products business Menlo Therapeutics (NASDAQ: MNLO) in an all-stock tran...
News, Short Squeeze, Breakout and More Instantly...
Foamix Pharmaceuticals Ltd. Company Name:
FOMX Stock Symbol:
NASDAQ Market:
REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address ...
REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address ...
REHOVOT, Israel, BRIDGEWATER, N.J. and REDWOOD CITY, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) and Menlo Therapeutics Inc. (Nasdaq: MNLO) today announced that the shareholders of Foamix and stockholders of Menlo voted to approve all shareholder and...